HRP980231B1 - Phosphodiesterase 4 - inhibiting diazepinoindolones - Google Patents

Phosphodiesterase 4 - inhibiting diazepinoindolones

Info

Publication number
HRP980231B1
HRP980231B1 HR980231A HRP980231A HRP980231B1 HR P980231 B1 HRP980231 B1 HR P980231B1 HR 980231 A HR980231 A HR 980231A HR P980231 A HRP980231 A HR P980231A HR P980231 B1 HRP980231 B1 HR P980231B1
Authority
HR
Croatia
Prior art keywords
formula
compounds
phosphodiesterase
diazepinoindolones
inhibiting
Prior art date
Application number
HR980231A
Other languages
English (en)
Inventor
Yves Pascal
Catherine Burnouf
Bernard Gaudilliere
Henry Jacobelli
Alain Calvet
Adrian Payne
Sven G Dahl
Original Assignee
Jouveinal S C A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jouveinal S C A filed Critical Jouveinal S C A
Publication of HRP980231A2 publication Critical patent/HRP980231A2/hr
Publication of HRP980231B1 publication Critical patent/HRP980231B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR980231A 1997-04-30 1998-04-29 Phosphodiesterase 4 - inhibiting diazepinoindolones HRP980231B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9705422A FR2762841B1 (fr) 1997-04-30 1997-04-30 Diazepino-indolones inhibitrices de phosphodiesterases iv

Publications (2)

Publication Number Publication Date
HRP980231A2 HRP980231A2 (en) 2000-04-30
HRP980231B1 true HRP980231B1 (en) 2002-06-30

Family

ID=9506517

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980231A HRP980231B1 (en) 1997-04-30 1998-04-29 Phosphodiesterase 4 - inhibiting diazepinoindolones

Country Status (17)

Country Link
US (1) US6239130B1 (OSRAM)
EP (1) EP0980374B1 (OSRAM)
JP (1) JP2001522367A (OSRAM)
KR (1) KR20010020386A (OSRAM)
AT (1) ATE232534T1 (OSRAM)
AU (1) AU729495B2 (OSRAM)
BR (1) BR9809429A (OSRAM)
CA (1) CA2278217A1 (OSRAM)
DE (1) DE69811360T2 (OSRAM)
DK (1) DK0980374T3 (OSRAM)
ES (1) ES2190083T3 (OSRAM)
FR (1) FR2762841B1 (OSRAM)
HR (1) HRP980231B1 (OSRAM)
MX (1) MXPA99006979A (OSRAM)
NZ (1) NZ337589A (OSRAM)
WO (1) WO1998049169A1 (OSRAM)
ZA (1) ZA983704B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795731B1 (fr) * 1999-07-02 2001-09-07 Warner Lambert Co PROCEDE DE PREPARATION DE [1,4] DIAZEPINO [6,7,1-hi] INDOL-4-ONES SUBSTITUEES
CA2401697A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
EP1161949A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
WO2002094321A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
WO2002094320A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Therapeutic compositions for repairing chondropathy
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20090042951A1 (en) * 2004-02-20 2009-02-12 Robert Danziger Blood Pressure Reduction in Salt-Sensitive Hypertension
WO2005102317A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
BRPI0610498A2 (pt) * 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US20090005381A1 (en) * 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
RU2012117141A (ru) * 2009-10-01 2013-11-10 Алькон Рисерч, Лтд. Композиции олопатадина и способы их применения
US12472241B2 (en) 2018-12-28 2025-11-18 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725719B1 (fr) * 1994-10-14 1996-12-06 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases iv

Also Published As

Publication number Publication date
NZ337589A (en) 2000-10-27
EP0980374A1 (en) 2000-02-23
FR2762841B1 (fr) 1999-07-02
ATE232534T1 (de) 2003-02-15
AU7765298A (en) 1998-11-24
JP2001522367A (ja) 2001-11-13
FR2762841A1 (fr) 1998-11-06
AU729495B2 (en) 2001-02-01
DK0980374T3 (da) 2003-05-05
US6239130B1 (en) 2001-05-29
MXPA99006979A (es) 2005-04-19
CA2278217A1 (en) 1998-11-05
BR9809429A (pt) 2000-06-13
HRP980231A2 (en) 2000-04-30
ES2190083T3 (es) 2003-07-16
DE69811360D1 (de) 2003-03-20
DE69811360T2 (de) 2003-10-09
WO1998049169A1 (en) 1998-11-05
ZA983704B (en) 1999-10-25
KR20010020386A (ko) 2001-03-15
EP0980374B1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
ZA983704B (en) Phosphodiesterase 4-inhibiting diazepinoindolones.
HU9601412D0 (en) Isoxazoline compounds as antiinflammatory agents
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
MX9805016A (es) INHIBIDORES DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1 beta.
BG102872A (en) 6-phenylpyridyl-3-amine derivatives
WO2003041643A3 (en) Hsp90-inhibiting zearalanol compounds and methods of producing and using same
EP1034164A4 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
BG104138A (en) 2-aminopyridines containing substituents with condensed rings as nos inhibitors
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
WO2004054501A3 (en) Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
IL112847A0 (en) Isoxazoline compounds as inhibitors of TNF release
BG104698A (en) Glucocorticoid-selective anti-inflammatory agents
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
MXPA97001884A (es) Composiciones para el tratamiento de trastornos enla piel.
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
YU18399A (sh) Postupak alkilacije zaštićenih sulfonamida
PL358552A1 (en) 2-aminoalkyl-thieno[2,3-d]pyrimidines
DE69929802D1 (en) Lta4 hydrolase-hemmer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040429

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20050430